Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial bone marrow stem cells for acute ischemic stroke
IRCT20140818018842N49Phase 2Completed
- Sponsor
- Motamed Cancer Institute
- Start
- Jul 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bone marrow stem cells in ischemic stroke (2 arms), sponsored by Motamed Cancer Institute. Primary endpoints: Safety of bleeding events, Lower extremity paralysis and 4 more. Started Jul 2025; status: completed.
02
Drugs
bone marrow stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20140818018842N49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N49.